Kiora director granted options for 25,000 shares

Kiora Pharmaceuticals director Carmine N. Stengone received a stock option grant as part of equity compensation.

Rhea-AI Filing Summary

Kiora Pharmaceuticals director Carmine N. Stengone received a stock option grant as part of equity compensation. On June 10, 2026, he was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, with no cash paid for the grant itself.

The options were granted under Kiora’s 2024 Equity Incentive Plan and will become fully exercisable on June 10, 2027. They expire on June 10, 2036 if not exercised. After this award, Stengone holds options for 25,000 underlying shares directly, and the filing does not report any open‑market purchases or sales.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Stengone Carmine N.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Key Figures

Options granted: 25,000 options Exercise price: $2.63 per share Underlying shares: 25,000 shares +4 more

7 metrics

Options granted 25,000 options Stock Option (right to buy) grant on June 10, 2026

Exercise price $2.63 per share Conversion or exercise price for the stock options

Underlying shares 25,000 shares Common stock underlying the option award

Grant date June 10, 2026 Option award transaction date

Vesting date June 10, 2027 Options become fully exercisable on this date

Expiration date June 10, 2036 Options expire if unexercised by this date

Options held after grant 25,000 options Total options following this reported transaction

Key Terms

Stock Option (right to buy), 2024 Equity Incentive Plan, exercise price, fully exercisable, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan."

exercise price financial

"conversion_or_exercise_price: "2.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully exercisable financial

"The Option will become fully exercisable on June 10, 2027."

expiration date regulatory

"expiration_date: "2036-06-10T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiora Pharmaceuticals (KPRX) director Carmine Stengone report in this Form 4?

Director Carmine N. Stengone reported receiving a stock option grant for 25,000 shares of Kiora Pharmaceuticals common stock. The options were issued as a compensation award under the company’s 2024 Equity Incentive Plan, not through an open‑market transaction.

How many Kiora (KPRX) shares are covered by Carmine Stengone’s new stock options?

The new stock option grant covers 25,000 shares of Kiora Pharmaceuticals common stock. These options give Stengone the right to buy that number of shares in the future at a fixed exercise price once they become exercisable.

What is the exercise price of Carmine Stengone’s Kiora (KPRX) stock options?

The options have an exercise price of $2.63 per share. This means Stengone can purchase Kiora common stock at $2.63 per share once the options vest and before they expire, regardless of the market price at that time.

When do Carmine Stengone’s Kiora (KPRX) stock options vest and become exercisable?

The stock options will become fully exercisable on June 10, 2027. Until that vesting date, Stengone cannot exercise the options, but after vesting he may choose to exercise any or all of the 25,000 optioned shares before expiration.

When do the newly granted Kiora (KPRX) stock options to Carmine Stengone expire?

The options expire on June 10, 2036 if they are not exercised. After that expiration date, Stengone will no longer have the right to purchase Kiora common stock under this particular 25,000‑share option grant.

Is Carmine Stengone’s Kiora (KPRX) Form 4 a stock purchase or a compensation award?

This Form 4 reflects a compensation award, not an open‑market stock purchase. Stengone received stock options at no cost on the grant date, giving him rights to buy Kiora shares later at a fixed exercise price of $2.63 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stengone Carmine N.

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CALIFORNIA 92024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.63	06/10/2026		A		25,000		06/10/2027(1)	06/10/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)